Logo
x

Search category

Subscribe Now

Mismatch Repair-Deficient

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab to Treat MSI-H or dMMR Solid Tumors

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab to Treat MSI-H or dMMR Solid Tumors

  • June 8, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.